Rational drug design for identifying novel multi-target inhibitors for hepatocellular carcinoma

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 9, 2012, Pages 1088-1097

  Temirak, Ahmed ^a,b   Abdulla, Mona ^a,b   Elhefnawi, Mahmoud ^a,b  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b Information Technology Institute   (Egypt)

Author keywords

Hepatocellular carcinoma; In silico ADMET; Pharmacophore based virtual screening; Rational multi targeting drug design; Sorafenib

Indexed keywords

AXITINIB; B RAF KINASE; BAX401; CEDIRANIB; GW78603; IMATINIB; LINIFANIB; MITOGEN ACTIVATED PROTEIN KINASE P38; MOTESANIB; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; RECETIN; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR 2; VATALANIB;

ALGORITHM; ARTICLE; COMPUTER MODEL; DATA BASE; DRUG BINDING SITE; DRUG DESIGN; DRUG TARGETING; HUMAN; LIVER CELL CARCINOMA; MOLECULAR DOCKING; PHARMACOPHORE; VALIDATION PROCESS;

CARCINOMA, HEPATOCELLULAR; DRUG DESIGN; HUMANS; LIVER; LIVER NEOPLASMS; MOLECULAR DOCKING SIMULATION; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS;

EID: 84872252371     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012803529718     Document Type: Article

References (39)

1. Huynh, H. Molecularly targeted therapy in hepatocellular carcinoma. Biochem. Pharmacol., 2010, 80, (5), 550-560.
2. Voigt, J. H.; Bienfait, B.; Wang, S.; Nicklaus, M. C. Comparison of the NCI Open Database with Seven Large Chemical Structural Databases. J. Chem. Inf. Model., 2001, 41, (3), 702-712.
3. Irwin, J. J.; Shoichet, B. K. ZINC--a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model., 2004, 45, (1), 177-82.
4. Butina, D. Unsupervised Data Base Clustering Based on Daylight's Fingerprint and Tanimoto Similarity: A Fast and Automated Way To Cluster Small and Large Data Sets. J. Chem. Inf. Model., 1999, 39 (4), 747-750.
5. Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. DrugBank 3.0: a comprehensive resource for "omics" research on drugs. Nucleic Acids Res., 2011, 39, D1035-D1041.
6. Lipinski, C. a; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. drug delivery rev., 2001, 46 (1-3), 3-26.
7. Huang, P.-W.; Lai, Y.-H. Effective segmentation and classification for HCC biopsy images. Pattern Recogn., 2010, 43 (4), 1550-1563.
8. Parkin, D. M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA-Cancer J. Clin., 2002, 55 (2), 74-108.
9. El-Serag HB, M. A. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med., 1999, 340 (10), 745-750.
10. Gotink, K. J.; Verheul, H. M. W. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis, 2010, 13 (1), 1-14.
11. Liao, J. J.-L. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J. med. chem., 2007, 50 (3), 409-424.
12. Zetter, B. R. Angiogenesis and tumor metastasis. Annu. Rev. Med., 1998, 49(1), 407-424.
13. Ma, X. H.; Shi, Z.; Tan, C.; Jiang, Y.; Go, M. L.; Low, B. C.; Chen, Y. Z. In silico approaches to multi-target drug discovery: computer aided multi-target drug design, multi-target virtual screening. Pharmaceut. Res., 2010, 27 (5), 739-749.
14. Krug M, Hilgeroth A. Recent advances in the development of multi-kinase inhibitors. Mini Rev. Med. Chem., 2008, 8 (2), 1312-1327.
15. Gill AL, Verdonk M, Boyle RG, Taylor R. A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr. Top Med. Chem., 2007, 7 (3) 1408-1422.
16. Simard, J. R.; Getlik, M.; Grütter, C.; Pawar, V.; Wulfert, S.; Rabiller, M.; Rauh, D. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors. J. Am. Chem. Soc.,2009, 131(137), 13286-13296.
17. Wan, P. T. C.; Garnett, M. J.; Roe, S. M.; Lee, S.; Niculescu-Duvaz, D.; Good, V. M.; Jones, C. M.; Marshall, C. J.; Springer, C. J.; Barford, D.; Marais, R. Mechanism of activation of the RAFERK signaling pathway by oncogenic mutations of B-RAF. Cell, 2004, 116 (6), 855-867.
18. Kinase Inhibitor Drugs; Li, R.; Stafford, J. A.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2009, pp. 113-130.
19. Molecular Operating Environment (MOE) 2008.10, Chemical Computing Group Inc., Quebec, Canada, 2008.
20. Llovet, JM.; Ricci S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, JF.;de Oliveira, AC.; Santoro, A.; Raoul, JL.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, TF.; Galle, PR.; Seitz, JF.;Borbath, I.; Haussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J. Sorafenib in advanced Hepatocellular carcinoma. N. Engl. J. Med., 2008, 359(4), 378-390.
21. Wilhelm, S.; Carter, C.; Lynch, M.; Lowinger, T.; Dumas, J.; Smith, RA.; Schwartz, B.; Simantov, R.; Kelley, S. Discovery and development of Sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov., 2006, 5(10), 835-844.
22. Kinase Inhibitor Drugs; Li, R.; Stafford, J. A.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2009, pp. 79-112.
23. Buchdunger, E.; Zimmermann, J.; Mett, H.; et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res., 1996, 56 (1), 100-104.
24. Buchdunger, E.; Cioffi, CL.; Law, N.; et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol Exp. Ther., 2000, 295 (1), 139-145.
25. Podar, K.; Tonon, G.; Sattler, M.; Tai, YT.; Legouill, S.; Yasui, H.; Ishitsuka, K.; Kumar, S.; Kumar, R.; Pandite, LN.; Hideshima, T.; Chauhan, D.; Anderson, KC. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc. Natl. Acad. Sci. U.S.A., 2006, 103 (51), 19478-19483.
26. Sloan, B.; Scheinfeld, NS. Pazopanib; a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr. Opin. Investig. Drugs., 2008, 9, (12), 1324-1335.
27. Polverino, A.; Coxon, A.; Starnes, C.; Diaz, Z.; DeMelfi, T.; Wang, L.; Bready J.; Estrada, J.; Cattley, R.; Kaufman, S.; Chen, D.; Gan, Y.; Kumar, G.; Meyer, J.; Neervannan, S.; Alva, G.; Talvenheimo, J.; Montestruque, S.; Tasker, A.; Patel, V.; Radinsky, R.; Kendall, R. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res., 2006, 66 (17), 8715-8721.
28. Scott, EN.; Meinhardt, G.; Jacques, C.; Laurent, D.; Thomas, AL. Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumors. Expert Opin. Investig. Drug., 2007, 16 (3), 367-379.
29. Wood, JM.; Bold, G.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Frei, J.; Hofmann, F.; Mestan, J.; Mett, H.; O'Reilly, T.; Persohn, E.; Rosel, J.; Schnell, C.; Stover, D.; Theuer, A.; Towbin, H.; Wenger, F.; Woods-Cook, K.; Menrad, A.; Siemeister, G.; Schirner, M.; Thierauch, KH.; Schneider, MR.; Drevs, J.; Martiny-Baron, G.; Totzke, F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res., 2000, 60 (108), 2178-2189.
30. Faivre, S.; Demetri, G.; Sargent, W.; Raymond, E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov., 2007, 6(9), 734-745.
31. Lindsay CR.; MacPherson IR.; Cassidy J. Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. Future Oncol., 2009, 5(4), 421-432.
32. Schiller, JH.; Larson, T.; Ou, SH.; Limentani, S.; Sandler, A.; Vokes, E.; Kim, S.; Liau, K.; Bycott, P.; Olszanski, AJ.; von Pawel, J. Efficacy and safety of axitinib in patients with advanced nonsmall-cell lung cancer: results from a Phase II Study. J. Clin. Oncol., 2009, 27(23), 3836-3841.
33. Hu-Lowe, DD.; Zou, HY.; Grazzini, ML.; Hallin, ME.; Wickman, GR.; Amundson, K.; Chen, JH.; Rewolinski, DA.; Yamazaki, S.; Wu, EY.; McTigue, MA.; Murray, BW.; Kania, RS.; O'Connor, P.; Shalinsky, DR.; Bender, SL. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin. Cancer Res., 2008, 14(22), 7272-7283.
34. Ciardiello, F.; Caputo, R.; Damiano, V.; Caputo, R.; Troiani, T.; Vitagliano, D.; Carlomagno, F.; Veneziani, BM.; Fontanini, G.; Bianco, AR.; Tortora, G. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res., 2003, 9(4), 1546-1556.
35. Dietrich, J.; Gokhale, V.; Wang, X.; Hurley, L. H.; Flynn, G. A. Application of a novel [3+2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFGout allosteric B-Raf inhibitors. Bioorg. Med. Chem., 2010, 18 (1), 292-304.
36. Varnek, A.; Gaudin, C.; Marcou, G.; Baskin, I.; Pandey, A. K.; Tetko, I. V. Inductive transfer of knowledge: application of multitask learning and feature net approaches to model tissue-air partition coefficients. J. Chem. Inf. Model., 2009, 49(1), 133-44.
37. Moda, T. L.; Torres, L. G.; Carrara, A. E.; Andricopulo, A. D. PK/DB: database for pharmacokinetic properties and predictive in silico ADMET models. Bioinformatics (Oxford, England), 2008, 24(19), 2270-1.
38. Hou, T.; Wang, J.; Zhang, W.; Xu, X. ADMET evaluation in drug discovery. 6. Can oral bioavailability in humans be effectively predicted by simple molecular property-based rules? J. Chem. inform. model., 2007, 47(2), 460-3.
39. Molecular Properties Prediction-Osiris Property Explorer. http://www.organic-chemistry.org/prog/peo/. (Accessed Oct 23, 2011)